EE673 Cost-Effectiveness Analysis of Pembrolizumab for First-Line Treatment in Patients With Persistent, Recurrent, and Metastatic Cervical Cancer in the United States: Results From the Final Analysis of Trial
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.938
https://www.valueinhealthjournal.com/article/S1098-3015(23)04068-8/fulltext
Title :
EE673 Cost-Effectiveness Analysis of Pembrolizumab for First-Line Treatment in Patients With Persistent, Recurrent, and Metastatic Cervical Cancer in the United States: Results From the Final Analysis of Trial
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04068-8&doi=10.1016/j.jval.2023.09.938
First page :
Section Title :
Open access? :
No
Section Order :
10429